
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

MINERALYS THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required
 - Fee paid previously with preliminary materials
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-

Your **Vote** Counts!

MINERALYS THERAPEUTICS, INC.

2026 Annual Meeting
Vote by May 20, 2026
11:59 PM ET



MINERALYS THERAPEUTICS, INC.
150 N. RADNOR CHESTER ROAD
SUITE F200
RADNOR, PA 19087

VB4367-P44982

You invested in MINERALYS THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 21, 2026.**

Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 7, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here to view materials and vote without entering a control number



Vote Virtually at the Meeting*

May 21, 2026
1:30 PM ET

Virtually at:
www.virtualshareholdermeeting.com/MLYS2026

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the more complete proxy materials that are available on the Internet or by mail. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). We encourage you to access and review all of the important information contained in the proxy materials before voting.

Voting Items	Board Recommends
1. Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders:	
Nominees:	
1a. Srinivas Akkaraju, M.D., Ph.D.	✔ For
1b. Brian Taylor Slingsby, M.D., Ph.D., M.P.H.	✔ For
1c. Daphne Karydas	✔ For
2. Ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.	✔ For
NOTE: In their discretion, the proxies are authorized to vote on any other business that may properly come before the meeting or any adjournment(s) thereof.	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".